摘要
Background Although PD-L1 expression is a crucial predictive biomarker for immunotherapy, it can be influenced by many factors. Methods A total of 248 Chinese patients with lung adenocarcinoma was retrospectively identified. Data for clinical features, gene alternations, signaling pathways and immune signatures was analyzed among negative expression group (TPS < 1%, n = 124), intermediate expression group (1% <= TPS < 50%, n = 93), and high expression group (TPS >= 50%, n = 38). Clinical outcomes among different expression groups were also evaluated from public database. Results Firstly, high tumor mutation burden was significantly associated with high PD-L1 expression in these Chinese patients with lung adenocarcinoma. In addition, gene alternations including TP53, PRKDC, KMT2D, TET1 and SETD2 apparently occurred in high PD-L1 expression group. Moreover, pathway analysis showed that mutations involving in DDR pathway, TP53 pathway, cell-cycle pathway and NOTCH pathway were obviously varied among three PD-L1 expression groups. Besides, most of patients in high PD-L1 expression group from TCGA database were determined as high-grade immune subtypes (C2-C4), showing significant higher proportions of IFN-gamma, CD8+ T-cells, NK cells, NK CD56 dim cells, Th1 cells, Th2 cells (P < 0.0001). Moreover, SETD2 mutation slightly correlated with overall survival from MSKCC cohort (HR 1.92 [95%CI 0.90-4.10], P = 0.085), and the percentage of IFN-gamma was significantly higher in SETD2 mutant group than in wild-type group (P < 0.01). Conclusions This study illustrated in-depth genomic correlates of PD-L1 expression in Chinese lung adenocarcinoma patients and relevant immune signatures from public database, which might interpret more potential molecular mechanisms for immunotherapy in NSCLC.
学科与关键词
- Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung CancerLi, Yue; Li, Chong; Jiang, Ya; Han, Xue; Liu, Sisi; Xu, Xiuxiu; Tang, Wanxiangfu; Ou, Qiuxiang; Bao, Hua; Wu, Xue; Shao, Yang; Xing, Minyan; Zhang, Yixiang*; Wang, Yuezhen*Journal of Oncology, 2022, 2022: 1763778.被引 1
- In-depth genomic characterization of programmed cell death ligand 1 (PD-L1) expression in Chinese lung adenocarcinoma patients.Kang, Li; Liu, Jun; Li, Jia; Wu, Lin; Xiao, Yajie; Du, Haijian; Zhao, Zhikun; Li, Xiaoting; Wu, Dongfang; Zhao, Zhuxiang; Chen, BolinVirtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2021-06-04 To 2021-06-08.
- Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlationsLi, Kai; Cao, Li; Li, Cheukfai; Wu, Jundong; Chen, Bo; Zhang, Guochun; Li, Xueri; Wen, Lingzhu; Jia, Minghan; Wei, Guangnan; Lin, Jiali; Li, Yingzi; Zhang, Yuchen; Mok, Hsiaopei; Ren, Chongyang; Wang, Yulei; Qi, Xiaofang; Guo, Lijie; Che, Yue; Liao, Ning*Cancer Medicine, 2023, 12(5): 5195-5208.
